DRD1 and schizophrenia: The authors of the DAR-0100A study emphasized the need for the development of novel dopamine D1 receptor agonists with improved pharmacokinetic properties, particularly with respect to half-life and oral bioavailability, and the need for a more comprehensive neuropsychological battery such as those assessed in 49 clinically stable individuals with schizophrenia treated with 0.5 or 15 mg of DAR-0100A [14].